全文获取类型
收费全文 | 934501篇 |
免费 | 66818篇 |
国内免费 | 1311篇 |
专业分类
耳鼻咽喉 | 13093篇 |
儿科学 | 24672篇 |
妇产科学 | 23628篇 |
基础医学 | 132924篇 |
口腔科学 | 28521篇 |
临床医学 | 80675篇 |
内科学 | 182885篇 |
皮肤病学 | 19371篇 |
神经病学 | 72093篇 |
特种医学 | 36939篇 |
外国民族医学 | 79篇 |
外科学 | 152938篇 |
综合类 | 18888篇 |
一般理论 | 242篇 |
预防医学 | 61722篇 |
眼科学 | 21409篇 |
药学 | 72687篇 |
3篇 | |
中国医学 | 2130篇 |
肿瘤学 | 57731篇 |
出版年
2018年 | 8810篇 |
2017年 | 6946篇 |
2016年 | 7679篇 |
2015年 | 8743篇 |
2014年 | 11937篇 |
2013年 | 17435篇 |
2012年 | 24060篇 |
2011年 | 25001篇 |
2010年 | 14748篇 |
2009年 | 14216篇 |
2008年 | 24566篇 |
2007年 | 25644篇 |
2006年 | 26429篇 |
2005年 | 25384篇 |
2004年 | 24513篇 |
2003年 | 23533篇 |
2002年 | 23084篇 |
2001年 | 54663篇 |
2000年 | 56442篇 |
1999年 | 46755篇 |
1998年 | 10261篇 |
1997年 | 8981篇 |
1996年 | 9124篇 |
1995年 | 8876篇 |
1994年 | 8248篇 |
1993年 | 7566篇 |
1992年 | 35454篇 |
1991年 | 33907篇 |
1990年 | 32717篇 |
1989年 | 31851篇 |
1988年 | 28971篇 |
1987年 | 28240篇 |
1986年 | 26274篇 |
1985年 | 25137篇 |
1984年 | 17813篇 |
1983年 | 15116篇 |
1982年 | 7763篇 |
1981年 | 6736篇 |
1979年 | 15756篇 |
1978年 | 10580篇 |
1977年 | 9018篇 |
1976年 | 7842篇 |
1975年 | 8608篇 |
1974年 | 10441篇 |
1973年 | 9838篇 |
1972年 | 9344篇 |
1971年 | 8842篇 |
1970年 | 8406篇 |
1969年 | 7905篇 |
1968年 | 7194篇 |
排序方式: 共有10000条查询结果,搜索用时 44 毫秒
1.
2.
Psychological mobile app for patients with acute myeloid leukemia: A pilot randomized clinical trial
Areej El-Jawahri MD Marlise R. Luskin MD Joseph A. Greer PhD Lara Traeger PhD Mitchell Lavoie BS Dagny Marie Vaughn BS Stephanie Andrews BS Daniel Yang BS Kofi Y. Boateng BS Richard A. Newcomb MD Nneka N. Ufere MD Amir T. Fathi MD Gabriela Hobbs MD Andrew Brunner MD Gregory A. Abel MD Richard M. Stone MD Daniel J. DeAngelo MD PhD Martha Wadleigh MD Jennifer S. Temel MD 《Cancer》2023,129(7):1075-1084
3.
4.
Eric T. Hyde MPH Andrea Z. LaCroix PhD MPH Kelly R. Evenson PhD MS Annie Green Howard PhD Blake Anuskiewicz MS Chongzhi Di PhD John Bellettiere PhD MPH Michael J. LaMonte PhD MPH JoAnn E. Manson MD MPH DrPH Julie E. Buring ScD Eric J. Shiroma ScD I-Min Lee MBBS ScD Humberto Parada Jr. PhD MPH 《Cancer》2023,129(10):1579-1590
5.
6.
7.
Tero Sievänen Tia-Marje Korhonen Tiina Jokela Maarit Ahtiainen Laura Lahtinen Teijo Kuopio Anna Lepistö Elina Sillanpää Jukka-Pekka Mecklin Toni T. Seppälä Eija K. Laakkonen 《International journal of cancer. Journal international du cancer》2023,152(5):932-944
Circulating microRNAs (c-miRs) are small noncoding RNA molecules that migrate throughout the body and regulate gene expression. Global c-miR expression patterns (c-miRnomes) change with sporadic carcinogenesis and have predictive potential in early detection of cancers. However, there are no studies that have assessed whether c-miRnomes display similar potential in carriers of inherited pathogenic mismatch-repair gene variants (path_MMR), known as Lynch syndrome (LS), who are predisposed to highly increased cancer risk. Using high-throughput sequencing and bioinformatic approaches, we conducted an exploratory analysis to characterize systemic c-miRnomes of path_MMR carriers, sporadic rectal cancer patients and non-LS controls. We showed for the first time that cancer-free path_MMR carriers have a systemic c-miRnome of 40 differentially expressed c-miRs that can distinguish them from non-LS controls. The systemic c-miRnome of cancer-free path_MMR carriers also resembles the systemic c-miRnomes of cancer patients with or without path_MMR. Our pathway analysis linked the found differentially expressed c-miRs to carcinogenesis. A total of 508 putative target genes were identified for 32 out of 40 differentially expressed c-miRs, and 238 of them were enriched in cancer-related pathways. The most enriched c-miR-target genes include well-known oncogenes and tumor suppressor genes such as BCL2, AKT3, PIK3CA, KRAS, NRAS, CDKN1A and PIK3R1. Taken together, our findings suggest that LS and sporadic carcinogenesis share common biological pathways and alterations in these pathways can produce a c-miR signature which can track potential oncogenic stress in cancer-free path_MMR carriers. Therefore, c-miRs hold potential in monitoring the LS risk stratification patterns during clinical surveillance or cancer management. 相似文献
8.
Alessandra Allione Clara Viberti Ilaria Cotellessa Chiara Catalano Elisabetta Casalone Giovanni Cugliari Alessia Russo Simonetta Guarrera Dario Mirabelli Carlotta Sacerdote Marco Gentile Fabian Eichelmann Matthias B. Schulze Sophia Harlid Anne Kirstine Eriksen Anne Tjønneland Martin Andersson Martijn E.T. Dollé Heleen Van Puyvelde Elisabete Weiderpass Miguel Rodriguez-Barranco Antonio Agudo Alicia K. Heath María-Dolores Chirlaque Thérèse Truong Dzevka Dragic Gianluca Severi Sabina Sieri Torkjel M. Sandanger Eva Ardanaz Paolo Vineis Giuseppe Matullo 《International journal of cancer. Journal international du cancer》2023,152(4):725-737
Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer mainly caused by asbestos exposure. Specific and sensitive noninvasive biomarkers may facilitate and enhance screening programs for the early detection of cancer. We investigated DNA methylation (DNAm) profiles in MPM prediagnostic blood samples in a case-control study nested in the European Prospective Investigation into Cancer and nutrition (EPIC) cohort, aiming to characterise DNAm biomarkers associated with MPM. From the EPIC cohort, we included samples from 135 participants who developed MPM during 20 years of follow-up and from 135 matched, cancer-free, controls. For the discovery phase we selected EPIC participants who developed MPM within 5 years from enrolment (n = 36) with matched controls. We identified nine differentially methylated CpGs, selected by 10-fold cross-validation and correlation analyses: cg25755428 (MRI1), cg20389709 (KLF11), cg23870316, cg13862711 (LHX6), cg06417478 (HOOK2), cg00667948, cg01879420 (AMD1), cg25317025 (RPL17) and cg06205333 (RAP1A). Receiver operating characteristic (ROC) analysis showed that the model including baseline characteristics (age, sex and PC1wbc) along with the nine MPM-related CpGs has a better predictive value for MPM occurrence than the baseline model alone, maintaining some performance also at more than 5 years before diagnosis (area under the curve [AUC] < 5 years = 0.89; AUC 5-10 years = 0.80; AUC >10 years = 0.75; baseline AUC range = 0.63-0.67). DNAm changes as noninvasive biomarkers in prediagnostic blood samples of MPM cases were investigated for the first time. Their application can improve the identification of asbestos-exposed individuals at higher MPM risk to possibly adopt more intensive monitoring for early disease identification. 相似文献
9.
Ziling Mao Jacqueline Roshelli Baker Masayoshi Takeuchi Hideyuki Hyogo Anne Tjønneland Anne Kirstine Eriksen Gianluca Severi Joseph Rothwell Nasser Laouali Verena Katzke Rudolf Kaaks Matthias B. Schulze Domenico Palli Sabina Sieri Maria Santucci de Magistris Rosario Tumino Carlotta Sacerdote Jeroen W. G. Derksen Inger T. Gram Guri Skeie Torkjel M. Sandanger Jose Ramón Quirós Marta Crous-Bou Maria-Jose Sánchez Pilar Amiano Sandra M. Colorado-Yohar Marcela Guevara Sophia Harlid Ingegerd Johansson Aurora Perez-Cornago Heinz Freisling Marc Gunter Elisabete Weiderpass Alicia K. Heath Elom Aglago Mazda Jenab Veronika Fedirko 《International journal of cancer. Journal international du cancer》2023,152(11):2257-2268
Glyceraldehyde-derived advanced glycation end products (glycer-AGEs) could contribute to colorectal cancer development and progression due to their pro-oxidative and pro-inflammatory properties. However, the association of glycer-AGEs with mortality after colorectal cancer diagnosis has not been previously investigated. Circulating glycer-AGEs were measured by competitive ELISA. Multivariable Cox proportional hazards models were used to calculate hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) for associations of circulating glycer-AGEs concentrations with CRC-specific and all-cause mortality among 1034 colorectal cancer (CRC) cases identified within the European Prospective Investigation into Cancer and Nutrition (EPIC) study between 1993 and 2013. During a mean of 48 months of follow-up, 529 participants died (409 from CRC). Glycer-AGEs were statistically significantly positively associated with CRC-specific (HRQ5 vs Q1 = 1.53, 95% CI: 1.04-2.25, Ptrend = .002) and all-cause (HRQ5 vs Q1 = 1.62, 95% CI: 1.16-2.26, Ptrend < .001) mortality among individuals with CRC. There was suggestion of a stronger association between glycer-AGEs and CRC-specific mortality among patients with distal colon cancer (per SD increment: HRproximal colon = 1.02, 95% CI: 0.74-1.42; HRdistal colon = 1.51, 95% CI: 1.20-1.91; Peffect modification = .02). The highest HR was observed among CRC cases in the highest body mass index (BMI) and glycer-AGEs category relative to lowest BMI and glycer-AGEs category for both CRC-specific (HR = 1.78, 95% CI: 1.02-3.01) and all-cause mortality (HR = 2.15, 95% CI: 1.33-3.47), although no statistically significant effect modification was observed. Our study found that prediagnostic circulating glycer-AGEs are positively associated with CRC-specific and all-cause mortality among individuals with CRC. Further investigations in other populations and stratifying by tumor location and BMI are warranted. 相似文献
10.
Li Dong Mari Nygård Nathalie C. Støer Ole Klungsøyr Bo T. Hansen 《International journal of cancer. Journal international du cancer》2023,153(2):399-406
Human papillomavirus (HPV) vaccine effectiveness may differ between settings. Here we present the first real-world effectiveness study of HPV vaccination on high-grade cervical lesions from Norway, among women who received HPV vaccine outside the routine program. We performed an observational study of all Norwegian women born 1975 to 1996 and retrieved individual data from nationwide registries on HPV vaccination status and incidence of histologically verified high-grade cervical neoplasia during 2006 to 2016. We estimated the incidence rate ratio (IRR) and 95% confidence intervals (CI) for vaccination vs no vaccination by Poisson regression stratified by age at vaccination <20 years and ≥20 years. The cohort consisted of 832 732 women, of which 46 381 (5.6%) received at least one dose of HPV vaccine by the end of 2016. The incidence rate of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) increased with age regardless of vaccination status and was highest at age 25 to 29, at 637/100 000 among unvaccinated women, 487/100 000 among women vaccinated before age 20 and 831/100 000 among women vaccinated at age 20 or older. The adjusted IRR of CIN2+ between vaccinated and unvaccinated women was 0.62 (95% CI: 0.46-0.84) for women vaccinated below age 20, and 1.22 (95% CI: 1.03-1.43) for women vaccinated at age 20 or older. These findings indicate that HPV vaccination among women too old to be eligible for routine HPV vaccination is effective among women who are vaccinated below age 20 but may not have the desired impact among women who are vaccinated at age 20 or older. 相似文献